Accounting for Stock-based Compensation	6 Months Ended
Jun. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Accounting for Stock-based Compensation	NOTE 13 – ACCOUNTING FOR STOCK-BASED COMPENSATION On April 4, 2018, the Company’s board of directors (the “board”) approved the 2018 Omnibus Incentive Plan (the “2018 Omnibus Plan”), which was subsequently approved by the Company’s stockholders and became effective on May 31, 2018 (the “Effective Date”). The 2018 Omnibus Plan replaced the previous 2010 Omnibus Incentive Plan (the “Prior Plan”). The 2018 Omnibus Plan was amended on May 28, 2020 to increase the number of shares available for issuance. The 2018 Omnibus Plan, as amended, allows the Company to grant 1,600,000 shares using stock options, stock appreciation rights, restricted stock, restricted stock units (“RSU”), performance units and performance share awards (“PSA”), cash-settled restricted stock units (“CSRSU”), and other stock-based awards to all officers, key employees, and non-employee directors of the Company. Outstanding shares granted under the Prior Plan, totaling 22,333 as of June 30, 2022, remain subject to its terms and conditions, and no additional awards from the Prior Plan are to be made after the Effective Date. As of June 30, 2022, the Company had approximately 812,251 shares available for grant under the 2018 Omnibus Plan. CSRSUs have no impact on the shares available for grant under the Omnibus Plan, nor on the calculated shares used in earnings per share calculations. During the six months ended June 30, 2022, the Company granted to its employees 117,196 shares in the form of RSUs with an average grant date fair value of $91.79, and the equivalent value of 62,840 shares in the form of CSRSUs with an average grant date fair value of $92.40. During the six months ended June 30, 2022, the Company also granted 35,705 shares in the form of PSAs to its employees with a grant date fair value of $93.97 per share. The RSUs, CSRSUs and PSAs granted are generally subject to service-based vesting conditions, with the PSAs also having performance-based vesting conditions. The performance conditions for the PSAs granted in 2022 have a performance period from January 1, 2022 through December 31, 2024 and performance conditions that are consistent with the PSAs granted in prior years. The Company recognized stock-based compensation expense of $4.4 million and $4.4 million for the three months ended June 30, 2022 and 2021, respectively, and $9.0 million and $10.6 million for the six months ended June 30, 2022 and 2021, respectively. Unrecognized compensation expense of approximately $16.4 million as of June 30, 2022 related to unsettled RSUs is expected to be recognized over a weighted-average period of 2.0 years. The unrecognized compensation expense related to CSRSUs totaled approximately $8.4 million at June 30, 2022 and is expected to be recognized over a weighted-average period of 1.8 years. Unrecognized compensation expense related to PSAs of approximately $5.2 million as of June 30, 2022 is expected to be recognized over a weighted-average period of 1.4 years.

Accounting for Stock-based Compensation

6 Months Ended

Jun. 30, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

NOTE 13 – ACCOUNTING FOR STOCK-BASED COMPENSATION

On April 4, 2018, the Company’s board of directors (the “board”) approved the 2018 Omnibus Incentive Plan (the “2018 Omnibus Plan”), which was subsequently approved by the Company’s stockholders and became effective on May 31, 2018 (the “Effective Date”). The 2018 Omnibus Plan replaced the previous 2010 Omnibus Incentive Plan (the “Prior Plan”). The 2018 Omnibus Plan was amended on May 28, 2020 to increase the number of shares available for issuance.

The 2018 Omnibus Plan, as amended, allows the Company to grant 1,600,000 shares using stock options, stock appreciation rights, restricted stock, restricted stock units (“RSU”), performance units and performance share awards (“PSA”), cash-settled restricted stock units (“CSRSU”), and other stock-based awards to all officers, key employees, and non-employee directors of the Company. Outstanding shares granted under the Prior Plan, totaling 22,333 as of June 30, 2022, remain subject to its terms and conditions, and no additional awards from the Prior Plan are to be made after the Effective Date. As of June 30, 2022, the Company had approximately 812,251 shares available for grant under the 2018 Omnibus Plan. CSRSUs have no impact on the shares available for grant under the Omnibus Plan, nor on the calculated shares used in earnings per share calculations.

During the six months ended June 30, 2022, the Company granted to its employees 117,196 shares in the form of RSUs with an average grant date fair value of $91.79, and the equivalent value of 62,840 shares in the form of CSRSUs with an average grant date fair value of $92.40. During the six months ended June 30, 2022, the Company also granted 35,705 shares in the form of PSAs to its employees with a grant date fair value of $93.97 per share. The RSUs, CSRSUs and PSAs granted are generally subject to service-based vesting conditions, with the PSAs also having performance-based vesting conditions. The performance conditions for the PSAs granted in 2022 have a performance period from January 1, 2022 through December 31, 2024 and performance conditions that are consistent with the PSAs granted in prior years.

The Company recognized stock-based compensation expense of $4.4 million and $4.4 million for the three months ended June 30, 2022 and 2021, respectively, and $9.0 million and $10.6 million for the six months ended June 30, 2022 and 2021, respectively. Unrecognized compensation expense of approximately $16.4 million as of June 30, 2022 related to unsettled RSUs is expected to be recognized over a weighted-average period of 2.0 years. The unrecognized compensation expense related to CSRSUs totaled approximately $8.4 million at June 30, 2022 and is expected to be recognized over a weighted-average period of 1.8 years. Unrecognized compensation expense related to PSAs of approximately $5.2 million as of June 30, 2022 is expected to be recognized over a weighted-average period of 1.4 years.